Development Of Next Generation Drugs For Chronic Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$632,726.00
Summary
Chronic myeloid leukaemia (CML) is one of the four most common types of leukaemia. With current therapies, 15–20% of patients newly diagnosed for CML will die in the next five years, and it is therefore vitally important to discover new treatments. The aim of this project is to develop a new generation of drugs to treat CML based on new approaches (i.e., different type of molecules and different binding site) that can combat the resistance acquired to the current treatments.
Design And Delivery Of Peptide-based Anti-cancer Grb7 Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$603,126.00
Summary
The Grb7 protein is overproduced in many types of cancer cells and plays a role in cancer cell growth and spread. The current proposal builds upon the discovery of a peptide-based Grb7 inhibitor that has anti-cancer activity. This proposal is to prepare more potent inhibitor molecules that can efficiently reach the target cancer cells. Such molecules will be used for the study of Grb7 and for the development of a new Grb7-based anti-cancer drug therapy.
Molecular And Structural Basis Of Signalling By TIR Domain-containing Adaptors In TLR Pathways
Funder
National Health and Medical Research Council
Funding Amount
$666,417.00
Summary
Humans first detect the presence of pathogens and respond to them through specific pathways termed innate immune pathways. The proposed research will study proteins that participate in these pathways, in particular their three-dimensional structures and how they interact with each other, to understand how they work together to mount an immune response, and to find ways to modulate this response in infectious diseases as well as chronic inflammatory diseases.